<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We have shown that <z:chebi fb="0" ids="3347">candesartan</z:chebi> decreases the <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001297'>stroke</z:hpo>-induced elevation of mean arterial blood pressure (MAP) in Wistar rats and improves functional outcome </plain></SENT>
<SENT sid="1" pm="."><plain>The aim of the present study was to determine whether the same benefit could be achieved in spontaneously hypertensive rats (SHR) </plain></SENT>
<SENT sid="2" pm="."><plain>Animals were subjected to middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) or sham for 3 h followed by reperfusion </plain></SENT>
<SENT sid="3" pm="."><plain>Either <z:chebi fb="0" ids="3347">candesartan</z:chebi> (0.1, 0.3, or 1.0 mg/kg) or saline was administered </plain></SENT>
<SENT sid="4" pm="."><plain>MAP of the rats was monitored by means of telemetry, and neurological function was assessed </plain></SENT>
<SENT sid="5" pm="."><plain><z:mpath ids='MPATH_124'>Infarct</z:mpath> size, <z:hpo ids='HP_0000969'>edema</z:hpo> formation, and <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> content in the ischemic hemisphere were evaluated 24 h after the <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>MAP of SHR increased immediately upon MCAO from 135 (baseline) to 189 mm Hg, and it remained elevated until reperfusion </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="0" ids="3347">Candesartan</z:chebi> <z:mp ids='MP_0004876'>decreased MAP</z:mp> in a dose-dependent manner, with a drop below baseline after a dose of 1.0 mg/kg </plain></SENT>
<SENT sid="8" pm="."><plain>SHRs experienced greater blood pressure (BP)-lowering effects of <z:chebi fb="0" ids="3347">candesartan</z:chebi> after <z:hpo ids='HP_0001297'>stroke</z:hpo> compared with a sham condition (p &lt; 0.0001) </plain></SENT>
<SENT sid="9" pm="."><plain>Neurological deficit after <z:hpo ids='HP_0001297'>stroke</z:hpo> was reduced in <z:chebi fb="0" ids="3347">candesartan</z:chebi>-treated animals, revealing a dose-dependent effect (p &lt; 0.01) </plain></SENT>
<SENT sid="10" pm="."><plain><z:mpath ids='MPATH_124'>Infarct</z:mpath> size, <z:hpo ids='HP_0000969'>edema</z:hpo> formation, and <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> content were <z:hpo ids='HP_0000001'>all</z:hpo> reduced by <z:chebi fb="0" ids="3347">candesartan</z:chebi> at doses of 0.1 and 0.3 mg/kg (p &lt; 0.05 for <z:hpo ids='HP_0000001'>all</z:hpo>) </plain></SENT>
<SENT sid="11" pm="."><plain><z:chebi fb="0" ids="3347">Candesartan</z:chebi> (1 mg/kg) was not different from saline </plain></SENT>
<SENT sid="12" pm="."><plain>Low doses of <z:chebi fb="0" ids="3347">candesartan</z:chebi> provide neurovascular protection after <z:hpo ids='HP_0001297'>stroke</z:hpo> in SHRs </plain></SENT>
<SENT sid="13" pm="."><plain>Caution is warranted because <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001297'>stroke</z:hpo> increases the sensitivity to BP lowering, which, in turn, increases the likelihood of overshooting </plain></SENT>
</text></document>